Apogee Therapeutics Overview
Apogee Therapeutics (APGE) has a P/E ratio of -31.1, below the sector sector average of 33.83.
Get informed when a big investor buys or sells
+ Follow-31.10
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Apogee Therapeutics (APGE) currently reports a P/E ratio of -31.1. That is below the sector sector average of 33.83. Use the charts on this page to explore Apogee Therapeutics's P/E ratio history and peer comparisons.
Apogee Therapeutics's P/E ratio of -31.1 is lower than the its sector sector average of 33.83. That is roughly 191.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Apogee Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -31.1, APGE can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -31.1, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 33.83. From there, open related valuation or income-statement pages for Apogee Therapeutics, and consider following APGE for alerts when major investors trade the stock.
